MNOV
MNOV clinical trials: MEDICINOVA INC
Every trial on ClinicalTrials.gov where MEDICINOVA INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 21
- Trials linked
- 17
- As lead sponsor
- 4
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
MNOV on the catalyst calendar · MNOV registry changes
- Primary completion Apr 2027Sponsor estimatePhase 2/Phase 3NCT04057898Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSMediciNova · Amyotrophic Lateral SclerosisActive, not recruitingMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT05464784MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaMediciNova · Diabetes Mellitus, Type 2Active, not recruitingMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 7, 2020ActualPhase 2NCT02503657Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary FibrosisMediciNova · Idiopathic Pulmonary FibrosisCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 7, 2023ActualPhase 1/Phase 2NCT03782415Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent GlioblastomaMediciNova · GlioblastomaCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2022ActualPhase 2NCT04429555Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDSMediciNova · Pneumonia, ViralCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2019ActualPhase 1/Phase 2NCT02714036A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)MediciNova · Amyotrophic Lateral SclerosisCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2018ActualPhase 2NCT02681055Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD SubjectsMediciNova · Non-alcoholic SteatohepatitisCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2017ActualPhase 2NCT02238626Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)MediciNova · Amyotrophic Lateral SclerosisCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 17, 2019ActualPhase 1NCT04054206Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy VolunteersMediciNova · Healthy VolunteersCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2017ActualPhase 2NCT01982942Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple SclerosisMediciNova · Multiple Sclerosis, Primary ProgressiveCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 6, 2018ActualPhase 1NCT03533387Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy VolunteersMediciNova · Healthy VolunteersCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2010ActualPhase 1NCT01013142Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)MediciNova · Chronic Obstructive Pulmonary DiseaseCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2012ActualPhase 2NCT00838591Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of...MediciNova · AsthmaCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2012ActualPhase 1NCT01551316Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) PatientsMediciNova · Chronic Obstructive Pulmonary DiseaseCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2006ActualPhase 2NCT00295854Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial CystitisMediciNova · Interstitial CystitisCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2008ActualPhase 2NCT00679263Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe AsthmaMediciNova · AsthmaCompletedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2009ActualPhase 2NCT00683449Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of AsthmaMediciNova · AsthmaTerminatedMNOVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06743776Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALSMayo Clinic · ALSNo longer availableMNOVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 19, 2023ActualPhase 2NCT03594435Ibudilast for the Treatment of Alcohol Use DisorderUniversity of California, Los Angeles · Alcohol Use DisorderCompletedMNOVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2013ActualPhase 1NCT01217970Safety Interaction Trial Ibudilast and MethamphetamineUniversity of California, Los Angeles · Methamphetamine-dependenceCompletedMNOVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 2NCT01740414Effects of Ibudilast on Oxycodone Self-administration in Opioid AbusersNew York State Psychiatric Institute · Opioid AbuseCompletedMNOVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 21 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner